. 2004 Sep 23;6(6):R535–R543. doi: 10.1186/ar1440

Table 2.

Detection of ANA and anti-dsDNA autoantibodies during infliximab treatment

	Number of positive sera	ANA	Anti-dsDNA autoantibodies
Infliximab RA (n = 24)	n ₀	9	1
	n_i12	12	10
	n_i24	13	13
	n _t	22	14
Infliximab AS (n = 15)	n ₀	2	2
	n_i12	8	3
	n_i24	11	4
	n _t	13	6
Control RA (n = 30)	n ₀	5	0
	n_i12	4	2
	n _t	9	2

ANA, antinuclear autoantibodies; anti-dsDNA, anti-double-stranded DNA autoantibodies; n₀, number of positive sera before treatment; n_i12, number of positive sera-induced autoantibodies after 12 months of treatment; n_i24, number of positive sera-induced autoantibodies after 24 months of treatment; n_t, number of positive sera before treatment plus number of induced autoantibodies during infliximab treatment.